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Objectives: Leukocyte trapping due to leukocyte-endothelial activation has been implicated as the cause of lipodermato- 
sclerosis and ulceration in patients with chronic venous disease. We investigated endothelial activity in normal controls 
and patients ubjected to short-term venous hypertension. 
Methods: Twenty-five normal volunteers and 30 patients with chronic venous disease divided into two groups: varicose 
veins with skin changes (LDS, n=15); and varicose veins without skin changes (VVs, n=15) were studied. Blood 
samples were taken from a foot vein before and after experimental venous hypertension. Plasma levels of ELAM-1 
(endothelial leukocyte adhesion molecule-i), ICAM-1 (intercellular adhesion molecule-i), VCAM-1 (vascular cell adhesion 
molecule-i), and yon Willebrand factor (vWf) was measured by an ELISA. 
Results: There was a significant rise in the plasma concentration of ELAM-1, ICAM-1 and VCAM-1 in patients and 
normal controls in response to venous hypertension. Basal levels of plasma VCAM-1 and vWf were higher in patients 
with LDS compared to patients with VVs. The magnitude of rise of VCAM-1 was greater in patients with LDS compared 
to patients with VVs (p = 0.01, Mann-Whitney U-test). There was no difference in the basal evels or in the magnitude 
of change in plasma ICAM-1 and ELAM-1 between the two patient groups. 
Conclusion: Venous hypertension results in endothelial ctivation which may aid endothelial-leukocyte adhesion. Patients 
with LDS exhibit increased VCAM-1, which is a counterligand for receptors expressed by monocytes and Iymphocytes 
signifying that these cells may be more important in the development ofskin changes. 
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Introduction 
The aetiology of skin damage in patients with chronic 
venous disease is incompletely understood. In 1987 
Moyses et al. 1 reported a reduction in the number of 
white cells leaving the feet in eight healthy subjects 
during a 45 min period of experimental venous hyper- 
tension. Thomas et al. 2 found a larger fall in a group 
of 10 patients with chronic venous insufficiency, and 
concluded that leukocytes were being sequestered in
the lower limb. Coleridge Smith et al. using video 
microscopy showed that the number of visible ca- 
pillaries fell during a period of venous hypertension, 
suggesting that increased venous pressure reduced 
capillary perfusion and hence the capillary flow rate. 
On the basis of these observations the white cell trap- 
ping hypothesis 3 was proposed, suggesting that raised 
venous pressure led to decreased flow, in turn causing 
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leukocyte margination, activation, adhesion, and extra- 
vascular migration. It was proposed that the release 
of proteolytic enzymes and free radicals from activated 
leukocytes resulted in tissue damage. This is supported 
by histological evidence of white cell infiltration of the 
tissues ~in skin biopsies from patients with venous 
disease. 
The molecular mechanism of leukocyte adhesion to 
vascular endothelial cells is the first critical step in 
leukocyte migration. Many adhesion molecules are 
expressed by circulating leukocytes and endothelial 
cells in response to physiological and pathological 
stimuli. These adhesion molecules are broadly divided 
into three groups - the Selectins, the Integrins, and 
the Immunoglobulin superfamily. A complex interplay 
of physical, biological, and biochemical factors control 
and modulate leukocyte-endothelial cell adhesion 
leading to leukocyte migration from the circulation 
into the tissues. Vascular endothelial cells commonly 
express the adhesion molecules ELAM-1 (endothelial 
leukocyte adhesion molecule-i, CD62E), ICAM-1 (in- 
tercellular adhesion molecule-I, CD54) and VCAM-1 
(vascular cell adhesion molecule-i, CD106), which are 
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Table 1. Duplex findings in patients. 
No. of pts Age SVI DVI + (SVI) Post 
Mean (range) thrombotic 
Gr 1-LDS 8F/7M 51 (32-69) 3 12 (10) 10 
Gr 2-VVs 7F/8M 48 (29-73) 13 2 (2) I 
all cell surface glycoproteins and expressed possibly in 
response to cytokine activation. 5 Endothelial adhesion 
molecules act as counter ligands to adhesion molecules 
expressed by leukocytes modulating leukocyte-endo- 
thelial adhesion and leukocyte emigration from the 
circulation into the tissues. 6 Von Willebrand factor, an 
endothelial cell product, stored in the Wiebel-Palade 
body and released into the circulation following endo- 
thelial cell injury, is a specific marker of endothelial cell 
damage. Although found in platelet alpha granules, 
plasmatic and platelet components of vWf are not 
interchangeable and the majority of circulating vWf is 
of endothelial cell origin. 7 Raised plasma levels have 
been reported in various clinical conditions where 
endothelial cell injury is suspected. 8"9 We have pre- 
viously demonstrated vidence of increased neutrophil 
degranulation i  normal subjects *°and patients 11"~2 with 
chronic venous disease in response to short-term ven- 
ous hypertension. We have reported increased ex- 
pression of the leukocyte adhesion molecule CD11b/ 
CD18 in normal volunteers ~3 and in patients with 
chronic venous disease 14'15 subjected to experimental 
short-term venous hypertension. We have also in- 
vestigated in vivo leukocyte migration in volunteers 
during short-term venous hypertension using the 
"Skin Window Technique". 16Leukocyte migration in 
the tissue decreased following experimental venous 
hypertension. ~7 
The aim of our present study was to investigate 
endothelial activity as an index of leukocyte-endo- 
thelial adhesion in normal controls and in patients 
with chronic venous disease subjected to short-term 
venous hypertension. We assessed endothelial ac- 
tivation by measuring the plasma levels of ELAM-1, 
ICAM-1, VCAM-1 and vWf before and after short- 
term venous hypertension. 
Materials and Methods 
The local ethics committee approved this study and 
written informed consent was obtained from all sub- 
jects participating in the study. Twenty-five normal 
volunteers (13 male and 12 female, mean age 31 years, 
range 20-59 years) and 30 patients (15M:15F, mean 
age 50 years, range 29-73 years) with chronic venous 
disease demonstrated by colour duplex ultra- 
sonography and photoplethysmography volunteered 
for inclusion in the study. The patients were further 
subdivided into two groups classified according to the 
severity of their disease (group 1 - lipodermato- 
sclerosis or haemosiderosis skin changes present, 
Hawaii (C.E.A.P.) clinical stage 4, LDS; group 2 - skin 
change absent, Hawaii clinical stage 2, VVs). 18 The 
duplex findings in the two groups are summarised in 
Table 1. Patients with history or clinical evidence of 
coexistent arterial disease, diabetes mellitus, con- 
nective tissue disorders including rheumatoid arthritis, 
blood disorders, infection within the previous 6weeks, 
or medication known to alter white cell activity were 
excluded from the study. 
Procedure 
An 18G cannula (Venflon 2, BOC Ohmeda, Hel- 
singborg, Sweden) was placed in the distal long sa- 
phenous vein or dorsal foot vein of one leg. The 
cannula was flushed with heparinised saline and the 
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Fig. 1. The white cell: red cell ratio during the experiment. De- 
scriptors are medians and interquartile ranges, statistics are Wil- 
coxon matched-pairs signed-rank test. L = lying; S = standing. 
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Table 2. Plasma ELAM-1, ]CAM-l, VCAM-1 and vWf in control subjects and patients with chronic venous disease, expressed as 
median (interquartille range), before and after venous hypertension produced by standing for 30 min. LDS = Lipodermatosclerotic 
skin changes; VVs = skin change absent; CI = confidence interval, Wilcoxon; N.S. = not significant. 
Molecule/vWf Controls Patients Mann-Whitney 
U-test LDS VVs 
ELAM 
Median (IQR) ng/ml 
Basal 
Standing 
Diff between median rise 
(95% CI, Wilcoxon) 
ICAM 
Median (IQR) ng/ml 
Basal 
Standing 
Diff between median rise 
(95% CI, Wilcoxon) 
VCAM 
Median (IQR) ng/ml 
Basal 
Standing 
Diff between median rise 





Diff between median rise 
(95% CI, Wilcoxon) 
41 (23-62)t,{ 57 (43-76)t 41 (34-59){ ~=0.01, {=N.S. 
52 (30-81)*,9 61 (49-87)* 51 (39-66)9 *=N.S., 9=N.S. 
11.5 (15--8) 3.5 (7-1) 6.75 (10-4) 
211 (196-229)-t,{ 267 (230-341)t 251 (238-294){ t = 0.002, { = 0.001 
272 (234-310)*,9 312 (277-387) ~ 288 (253-363)9 * =0.03, 9=N.S. 
60 (73.5-47) 34.8 (62-15) 34.8 (60-5.5) 
394 (333-445)+,{ 607 (552-776)4- 513 (432-699){ t = 0.003, { = 0.01 
559 (413-696)*,9 899 (705-971)* 651 (505-907)9 *<0.001, 9=N.S. 
144 (214-73.5) 202 (273.5-157) 103 (165-67.5) 
138(108-166)§ 80 (61-105)§ §=0.002 
141 (100-169){{ 92 (46-127){{ {{ = 0.009 
N.S. N.S. 
P values - t = controls vs. LDS; $ = controls vs. VVs; *= controls vs. LDS; 9 = controls vs. VVs; § = LDS vs. VVs; {{ = LDS vs. VVs. 
2 ml of blood were taken and discarded from the 
cannula and a further 8 ml collected into two tubes 
containing EDTA (Vacutainer, Becton Dickinson Va- 
cutainer Systems Europe, BP No 37-38241 Meylan 
Cedex, France). The subject then stood supported 
against he side of the couch for 30 min without moving 
the calf muscles. We have previously shown by direct 
pressure measurement that this raises the venous pres- 
sure in the superficial veins of the leg to between 
70-80 mmHg]  9'2° Following this a second blood sample 
was taken. 
A full blood count, including a differential white 
cell count, was performed on all subjects (Sysmex SE- 
9000, Sysmex (U.K.) Ltd, Milton Keynes, U.K.). Plasma 
from the samples were separated by centrifugation 
and stored at -20  °C. ELAM-1, ICAM-1 and VCAM- 
1 were measured by commercial ly available ELISAs 
(R&D Systems Europe, Oxon, U.K.) once all samples 
were collected. Von Willebrand factor was measured 
in patients only as a later addition after an assay with 
commercial antisera (Dako Ltd, U.K.) was optimised 
in our research laboratory. At present there is no 
commercial ly available ELISA kit for von Willebrand 
factor in the market. 
Analysis of data 
The Statistical Package for the Social Sciences (SPSS, 
Chicago, Illinois, U.S.A.) was used to analyse the data 
and non-parametric tests for paired and unpaired 
data (Wilcoxon matched-pairs signed-rank test and 
Mann-Whitney U-test) were used. The difference be- 
tween median and 95% confidence interval were cal- 
culated using Wilcoxon method Confidence Interval 
Analysis (British Medical Journal, London). All results 
are described as median (interquartile range, IQR). 
Results 
Full blood count on samples taken during the ex- 
periment showed a rise in the haemoglobin, red cell 
count, white cell count and haematocrit on standing. 
The magnitude of the increase in white cell numbers 
during standing was less than that of the haemoglobin, 
red cell count or haematocrit. Leukocyte trapping 
during the experiment was confirmed by calculating 
the white cell:red cell ratio, which is shown in Fig. 1. 
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Fig. 2. Plasma ELAM-1 levels in normal controls and patients 
with chronic venous disease, before and after venous hypertension 
produced by standing for 30 rain. Descriptors are medians and 
interquartile ranges, statistics are Wilcoxon matched-pairs signed- 
rank test and Mann-Whitney U-test for unpaired data. L=lying; 
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Fig. 4. Plasma ICAM-I levels in normal controls and patients with 
chronic venous disease, before and after venous hypertension pro- 
duced by standing for 30 min. Descriptors are medians and in- 
terquartile ranges, statistics are Wilcoxon matched-pairs signed- 
rank test and Mann-Whitney U-test for unpaired data. L=lying; 
S = standing. * p = 0.0001, Mann-Whitney. 
In both normal controls and patients the white cell: 
red cell ratio fell significantly in response to venous 
hypertension, confirming that leukocyte sequestration 
had occurred in the lower limb. There was no sig- 
nificant difference in leukocyte sequestration between 
the LDS and VV group. 
The results are summarised in Table 2. There was a 
significant rise in the plasma concentration of ELAM- 
1, ICAM-1, and VCAM-1, in normal controls and both 
patient groups in response to experimental venous 
hypertension. Basal levels of all three adhesion 
molecules were significantly higher in patients com- 
pared to control subjects (Figs 2, 4 and 6). In patients 
with LDS basal plasma VCAM-1 and its magnitude 
180 
150 L p = 0.02, Wilcoxon 





p = 0.001, Wilcoxon 
LDS VVs 
L S L S 
Fig. 3. Plasma ELAM:I levels in patients with chronic venous disease, 
before and after venous hypertension produced by standing for 30 min. 
Descriptors are medians and interquartile ranges, statistics are Wil- 
coxon matched-pairs signed-rank test. L = lying; S = standing; LDS = 
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Fig. 5. Plasma ICAM-1 levels in patients with chronic venous disease, 
before and after venous hypertension produced by standing for 
30 rain. Descriptors are medians and interquartile ranges, statistics 
are Wilcoxon matched-pairs signed-rank test. L = lying; S = standing; 
LDS = lipodermatosclerotic skin changes; VVs = skin change absent. 
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*p = 0.001, Mann-Whitney 
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Fig. 6. Plasma VCAM-1 levels in normal controls and patients 
with chronic venous disease, before and after venous hypertension 
produced by standing for 30 min. Descriptors are medians and 
interquartite ranges, statistics are Wilcoxon matched-pairs signed- 
rank test and Mann-Whitney U-test for unpaired ata. L=lying; 
S = standing. * p = 0.001, Mann-Whitney. 
of rise in response to experimental  venous hyper-  
tension was significantly higher compared  to patients 
with VVs (Fig. 7). There was no difference in the 
magni tude of change in ICAM-1 and ELAM-1 between 









*p = 0.01, Mann-Whitney 
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Fig. 7. Plasma VCAM-1 levels in patients with chronic venous 
disease, before and after venous hypertension produced by standing 
for 30 rain. Descriptors are medians and interquartile ranges, stat- 
istics are Wilcoxon matched-pairs signed-rank test and Mann- 
Whitney U-test for unpaired data. L=lying; S=standing; LDS= 
lipodermatosclerotic skin changes; VVs = skin change absent. * p = 
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Fig. 8. Plasma vWf levels in patients with chronic venous disease, 
before and after venous hypertension produced by standing for 
30 rain. Descriptors are medians and interquartile ranges, statistics 
are Mann-Whitney U-test for unpaired ata. L = lying; S = standing; 
LDS = lipodermatosclerotic skin changes; VVs = skin change absent. 
* p =0.002, Mann-Whitney; t p = 0.01, Mann-Whitney. 
LDS, however,  had significantly raised plasma vWf  
compared to patients in the VVs group, but  no sig- 
nificant change was noted in either group in response 
to short term experimental  venous hypertens ion (Fig. 
8). The experiment was repeated in five volunteers 
lying supine for the entire period. No  change was noted 
in the p lasma concentrat ion of the var ious adhesion 
molecules (data not shown). 
Discussion 
Chronic venous insufficiency and its sequelae such as 
l ipodermatosclerosis and venous ulceration is a major 
healthcare prob lem in the Western World. Two recent 
surveys in Great Britain have calculated the prevalence 
of venous ulceration as 0.18% and 0.148% re- 
spectively. 21'22 In the U.K. alone over £600 mil l ion is 
spent annual ly  to care for patients suffering with 
venous ulcers. 23 Much  of this is spent on care in the 
community ,  with 30% of communi ty  nurs ing time 
spent on treating leg ulcers. 
The precise sequence of events result ing in skin 
damage in patients with chronic venous disease has 
not been fully elucidated. The "white cell t rapping 
hypothesis"  suggests that raised venous pressure ini- 
tiates leukocyte activation and extra-vascular mi- 
gration, with the release of proteolytic enzymes and 
free radicals result ing in tissue damage. A l though 
Dutrochet in 1824 reported leukocyte migrat ion from 
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the circulation into the tissues, 24 the mechanism of 
such emigration has only recently been explained. 
Both leukocytes and the vascular endothelium express 
adhesion promoting receptors that mediate cell-cell 
and cell-matrix interaction, in response to various 
stimuli. These interactions are crucial for the direction 
and control of leukocyte traffic, migration through 
tissues, and the development of immune and non- 
immune inflammatory responses. Several families of 
adhesion receptors have been identified, of which the 
main are the Integrins, the Immunoglobulin super- 
families and the Selectins. Adhesion molecules on the 
endothelium act as counter ligands to those expressed 
on leukocytes and is the underlying mechanism for 
leukocyte-endothelial adhesion that occurs in the 
microcirculation. 25,26 
The endothelial adhesion molecules VCAM-1, 
ICAM-1 and ELAM-1 are all cell surface glygoproteins 
expressed on vascular endothelial cells in response 
to cytokine activationY 7 ELAM-1, a member of the 
Selectin family, is a 115 kDa cell surface glycoprotein 
transiently expressed on vascular endothelial cells in 
response to various cytokines uch as IL-1 and TNF- 
a.2s The lectin domain on ELAM-1 binds to the CD62L 
molecules expressed on neutrophils and monocytes 
initiating neutrophil rolling. ICAM-1, a member of the 
Immunoglobulin superfamily, is a 95 kDa cell surface 
glycoprotein which is constitutively expressed on some 
tissues and induced on others by pro-inflammatory 
cytokines. It is involved in adhesion of leukocytes 
in its role as a ligand for CD11a/CD11b receptors 
(members of the Integrin family), a9 and is present on 
a variety of cells including endothelium, macrophages, 
T and B cells, thymic endothelium and certain tumour 
cell lines? ° It also plays a role in granulocyte x- 
travasation through endothelium. VCAM-1, a member 
of the Immunoglobulin superfamily, is a 90 kDa cell 
surface glycoprotein, expressed by a number of cells 
including endothelium, macrophages, kidney epi- 
thelia, dendritic cells, myoblasts and bone marrow 
fibroblasts. It is expressed by vascular endothelial cells 
in response to cytokines and plays a major role in 
the adhesion of leukocytes to the endothelium by 
interaction with its ligand VLA, a member of the [31 
integrin family, which is expressed by monocytes and 
lymphocytes. 
VCAM-1, ICAM-1 and ELAM-1 exist in soluble 
form, 31'32 and have been shown to be elevated in a 
variety of inflammatory diseases and malignancies. 33'34 
The mechanism of release is unclear, but is probably 
due to proteolytic leavage from the cell surface. The 
reason for release of endothelial adhesion molecules 
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Fig. 9. Plasma ELAM-1 plotted against age for 25 control subjects. 
cells due to inflammatory episodes or it may provide 
a means to control adhesive interactions between cells. 
Recombinant soluble endothelial adhesion molecules 
has been shown to partially block adhesion of leu- 
kocytes, g5 They may also have their own biological 
function, as soluble ELAM-1 has been shown to act as 
a neutrophil chemoattractant. 36 ELAM-1 expression is
restricted to endothelial cells, and elevated levels could 
possibly represent a specific marker for endothelial 
damage or activation. 
In this experiment we noted a rise in the plasma 
levels of all three endothelial adhesion molecules in 
response to short-term venous hypertension, in both 
normal controls and in patients uffering from chronic 
venous disease, signifying endothelial activation. We 
have previously investigated and reported evidence 
of increased leukocyte activation in the same groups 
of normal controls and patients in response to ex- 
perimental venous hypertension by measuring the 
leukocyte surface adhesion molecules CD11b and 
CD62L on neutrophils and monocytes. ~3'14 Our pre- 
vious and present findings considered together pro- 
vide conclusive evidence of leukocyte-endothelial 
activation in the microcirculation ofthe leg in response 
to venous hypertension. Furthermore, the basal evels 
of all three endothelial adhesion molecules in the 
plasma was significantly higher in the patient group 
as a whole compared to normal controls, possibly 
signifying chronic stimulation of the vascular endo- 
thelium in such patients and therefore increased pro- 
pensity towards leukocyte adhesion. We had difficulty 
in recruiting exact age-matched controls (patients 
mean age 50 years, cf controls 31 years) but found a 
negative correlation with increasing age in the case of 
ELAM-1 (Fig. 9) and no correlation with age in the 
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Fig. 11. Plasma VCAM-1 plotted against age for 25 control subjects. 
skin changes. This is supported by our previous histo- 
logical evidence of monocyte infiltration into tissues 
in skin biopsies from patients with established skin 
changes due to chronic venous disease. 4 As such, 
plasma VCAM-1 levels may act as a marker to identify 
patients at risk of developing skin changes. 
Conclusion 
Elevated levels of adhesion molecules and vWf suggest 
that endothelial activation is a feature of chronic ven- 
ous disease. The source of the increase is unclear but 
presumably reflects endothelial damage in the skin, 
which is corroborated by histological evidence. The 
response to venous hypertension suggests further that 
increased leukocyte-endothelial interaction occurs in 
response to short-term venous hypertension. Endo- 
thelial injury may be the consequence of free radical 
release from activated leukocytes or due to the action 
of proteolytic neutrophil enzymes, although the mech- 
anism is not entirely clear. Patients in the LDS group 
had higher basal levels of vWf and VCAM-1, sug- 
gesting endothelial damage and monocyte adhesion. 
Our previous histological studies have shown that 
there is a perivascular macrophage infiltration in the 
skin capillaries. Perhaps part of the mechanism by 
which they reach this location is by the increased 
expression of VCAM-1 by the endothelium. These 
findings suggest hat leukocyte sequestration and ac- 
tivation together with endothelial activation in chronic 
venous disease is probably part of the mechanism that 
causes failure of the microcirculation resulting in skin 
ulceration. 
case of ICAM-1 (Fig. 10) and VCAM-1 (Fig. 11). We 
base our conclusions on the changes in plasma levels 
following venous hypertension rather than the ab- 
solute levels. Within the patient groups plasma VCAM- 
1 was significantly higher in the LDS group and the 
magnitude of rise in plasma VCAM-1 level in response 
to short-term venous hypertension was also sig- 
nificantly greater compared to patients with VVs with- 
out any skin changes. In the LDS group 10 out of 15 
patients had evidence of previous DVT. However, 
none of the patients with post thrombotic vein damage 
had suffered recent venous thrombosis and it is un- 
likely that an old deep vein thrombosis would modify 
these measurements. As VCAM-1 is the counter ligand 
for VLA receptors expressed by monocytes, it appears 
that although neutrophils may be important in the 
initial phase, monocyte infiltration of the tissues may 
be more important in patients who go on to develop 
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